# US 2016/0250203 A1 · Immediate release abuse-deterrent granulated dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250203 A1
- Document ID: US20160250203A1
- Status: Published application
- Kind: A1
- Application number: 15/032,658
- Filed: 2014-10-29
- Published: 2016-09-01
- Earliest claimed: 2013-10-31
- Assignees: Cima Labs Inc.
- Applicants: Cima Labs Inc.
- Inventors: Dinesh K. HASWANI; Derek V MOE; Victoria A. O'NEILL; Manuel A. VEGA ZEPEDA
- Web page: https://patentgrep.com/patent/US20160250203A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5078: {with drug-free core}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.

## Claims

### Claim 1

An immediate release abuse deterrent dosage form comprising:
a) core-shell particles, the core-shell particles comprising:
a core, the core comprising a gelling polymer, wherein the gelling polymer in the core is selected from a natural starch, a synthetic starch, a natural cellulose, a synthetic cellulose, an acrylate, a polyalkylene oxide, a carbomer and combinations thereof;
an active pharmaceutical layer surrounding the core, the active pharmaceutical layer comprising a narcotic analgesic;
at least one layer surrounding the active pharmaceutical layer, the at least one layer comprising a pH-sensitive film comprising pH-sensitive polymer that is insoluble in water at a pH greater than 5 and is soluble in water at a pH below 5; and
b) a matrix comprising a disintegrant and a gelling polymer; wherein the gelling polymer in the matrix is selected from a natural starch, a synthetic starch, a natural cellulose, a synthetic cellulose, an acrylate, a polyalkylene oxide, a carbomer, and combinations thereof.

### Claim 2 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein less than 5 weight percent of the total amount of the narcotic analgesic in the core shell particles is contained in the core.

### Claim 3 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein at least 90 percent of the total amount of the narcotic analgesic in the core shell particles is contained in the active pharmaceutical layer.

### Claim 4 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, further comprising a second type of core-shell particles that do not contain an active pharmaceutical layer, the second type of core-shell particles comprising:
a core, the core comprising a gelling polymer, wherein the gelling polymer in the core is selected from a natural starch, a synthetic starch, a natural cellulose, a synthetic cellulose, an acrylate, a polyalkylene oxide, a carbomer and combinations thereof; and
at least one layer surrounding the core, the at least one layer comprising a pH-sensitive film comprising pH-sensitive polymer that is insoluble at a pH greater than 5 and is soluble at a pH below 5.

### Claim 5 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the narcotic analgesic is an opioid.

### Claim 6 (depends on 5)

The immediate release abuse deterrent dosage form according to claim 5, further comprising a nonsteroidal analgesic drug.

### Claim 7 (depends on 5)

The immediate release abuse deterrent dosage form according to claim 5, wherein the opioid is selected from buprenorphine, codeine, dihydrocodeine, dihydromorphine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 6)

The immediate release abuse deterrent dosage form according to claim 6, wherein the nonsteroidal analgesic drug is selected from acetaminophen, aspirin, ibuprofen and naproxen.

### Claim 9 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the gelling polymer in the core is selected from ethylcellulose, cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, cellulose ether, cellulose ester, cellulose ester ether, cellulose, an acrylic acid and methacrylic acid copolymer, a methyl methacrylate copolymer, an ethoxyethyl methacrylate, a cyanoethyl methacrylate, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), glycidyl methacrylate copolymer, agar, acacia, karaya, tragacanth, algin, guar; polyacrylamide; water-swellable indene maleic anhydride polymer, hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, polyvinyl alcohol and combinations thereof.

### Claim 10 (depends on 9)

The immediate release abuse deterrent dosage form according to claim 9, wherein the gelling polymer in the core is selected from hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, polyvinyl alcohol and combinations thereof.

### Claim 11 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the gelling polymer in the core is present in an amount from 0.5 to 15 weight percent based on the total weight of the dosage form.

### Claim 12 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the gelling polymer in the matrix is selected from ethyl cellulose, cellulose acetate, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, cellulose ether, cellulose ester, cellulose ester ether, cellulose, an acrylic acid and methacrylic acid copolymer, a methyl methacrylate copolymer, an ethoxyethyl methacrylate, a cyanoethyl methacrylate, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), glycidyl methacrylate copolymer, agar, acacia, karaya, tragacanth, algin, guar; polyacrylamide; water-swellable indene maleic anhydride polymer, hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, polyvinyl alcohol and combinations thereof.

### Claim 13 (depends on 12)

The immediate release abuse deterrent dosage form according to claim 12, wherein the gelling polymer in the matrix is selected from hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, and combinations thereof.

### Claim 14 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the gelling polymer in the matrix is present in an amount from 0.5 to 15 weight percent based on the total weight of the dosage form.

### Claim 15 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the disintegrant in the matrix is selected from corn starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and combinations thereof.

### Claim 16 (depends on 15)

The immediate release abuse deterrent dosage form according to claim 15, wherein the dosage form comprises from 0.5 to 50 weight percent disintegrant based on total weight of the dosage form.

### Claim 17 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the pH-sensitive polymer is a copolymer of dimethyl aminoethyl methacrylate, butyl methacrylate, and methyl methacrylate monomers.

### Claim 18 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the dosage form excludes an emetic, a nasal irritant, an opioid antagonist, and an effervescent.

### Claim 19 (depends on 1)

The dosage form according to claim 1, wherein the dosage form, if ground and combined with a small volume of a solvent selected from ethanol, methanol, water, or a mixture thereof forms a composition having a viscosity that prevents uptake of the composition by a hypodermic syringe.

### Claim 20 (depends on 1)

The dosage form according to claim 1, wherein the dosage form reduces the risk of an overdose of the narcotic analgesic by simultaneous oral ingestion of multiple units of the oral dosage form.

### Claim 21 (depends on 1)

The dosage form according to claim 1, wherein the dosage form reduces the potential for abuse by simultaneous oral ingestion of multiple units of the oral dosage form.

### Claim 22 (depends on 1)

The dosage form of claim 1, wherein the dosage form is capable of releasing at least 75 weight percent of the narcotic analgesic into an aqueous hydrochloric acid solution within 240 minutes, the solution having a pH between 1 and 2 and a temperature of about 37 degrees Celsius.

### Claim 23 (depends on 1)

An immediate release abuse deterrent dosage form according to claim 1, that demonstrates an immediate release profile when administered in therapeutic doses, but which demonstrates an extended release profile when administered in supratherapeutic doses.

### Claim 24 (depends on 23)

The immediate release abuse deterrent dosage form according to claim 23, wherein the immediate release profile is defined as not less than 90% of API released in 60 minutes, and the extended release profile is defined as not more than 95% released in 60 minutes, wherein the release profiles may be evaluated by dissolution in 300 mL of 0.1N HCl media using USP II apparatus at 50 RPM paddle speed and 37° C.

### Claim 25 (depends on 23)

The immediate release abuse deterrent dosage form according to claim 23, wherein the supratherapeutic dose is five or more tablets.

### Claim 26 (depends on 1)

The immediate release abuse deterrent dosage form according to claim 1, wherein the dosage form is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

### Claim 27 (depends on 26)

The immediate release abuse deterrent dosage form according to claim 26, wherein the dosage form is in a compressed tablet form.

### Claim 28 (depends on 1)

A method of preventing, alleviating, or ameliorating a level of pain in a subject, the method comprising administering to the subject a dosage form as recited at claim 1.

### Claim 29 (depends on 1)

A method of preventing abuse of a narcotic analgesic drug comprising providing an immediate release abuse deterrent dosage form according to claim 1.

### Claim 30 (depends on 1)

A method of preventing overdose by accidental or intentional administration of a supratherapeutic dose of a narcotic analgesic drug, comprising providing an immediate release abuse deterrent dosage form according to claim 1.
